Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

Analytics

Trial Phases

Phase 13
Phase 24
Phase 31

Trial Status

Completed5
Recruiting1
Terminated1
Other1

Role Distribution

Principal Investigator8
PI Rate100%

Activity Timeline

Clinical Trials (8)

NCT07623135Phase 3Recruiting
Lumateperone for Late-Life Depression
Depression / Major Depressive DisorderLate Life Depression (LLD)Treatment Resistant Depression (TRD)
PrincipalinvestigatorStart date: 2026-09-01
NCT05124132Not ApplicableEnrolling By Invitation
Resilience and Brain Health of Older Adults (MEDEX-2)
Age-related Cognitive Decline
PrincipalinvestigatorStart date: 2019-04-16
NCT02181231Phase 1/2Completed
Buprenorphine Used With Treatment Resistant Depression in Older Adults
DepressionMajor Depressive Disorder
PrincipalinvestigatorStart date: 2016-06-01
NCT02665481Not ApplicableCompleted
Mindfulness-Based Stress Reduction, Health Education and Exercise
Age-related Cognitive Decline
PrincipalinvestigatorStart date: 2015-04-01
NCT02099825Phase 1Terminated
Medication Enhanced Rapid Therapy
Anxiety Disorders
PrincipalinvestigatorStart date: 2014-01-13
NCT00951691Phase 2Completed
Enhanced Medical Rehabilitation for Disablement
DepressionHip Fracture
Principalinvestigator

Research Network

Collaboration Network

1 collaborators·0 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Sabine Hazan, MD

ProgenaBiome

Related
41 trials

Shared therapeutic areas:

COVID-19Major Depressive DisorderCoronavirus+2 more
Similarity Score15%

Mark George, MD

Medical University of South Carolina

Related
6 trials

Shared therapeutic areas:

DepressionDepression - Major Depressive DisorderMajor Depressive Disorder+1 more
Similarity Score12%

Carlos A Zarate, M.D.

National Institute of Mental Health (NIMH)

Related
19 trials

Shared therapeutic areas:

DepressionMajor Depressive DisorderAnxiety Disorders+1 more
Similarity Score12%

Yair bAR-hAIM, PhD

Tel Aviv University

Related
18 trials

Shared therapeutic areas:

Anxiety DisordersDepressionMajor Depressive Disorder
Similarity Score9%

Charles Conway, MD

Washington University School of Medicine

Related
6 trials

Shared therapeutic areas:

Depressive Disorder, Treatment-ResistantMajor Depressive DisorderDepression

Worked with same sponsors:

Washington University School of Medicine
Similarity Score9%

Robert B Innis, M.D.

National Institute of Mental Health (NIMH)

Related
35 trials

Shared therapeutic areas:

DepressionAnxiety DisordersMajor Depressive Disorder
Similarity Score9%

Michael B Gill

Power Life Sciences Inc.

Related
105 trials

Shared therapeutic areas:

Anxiety DisordersDepressionDepressive Disorder, Treatment-Resistant
Similarity Score9%

Gerhard Andersson, Professor

Linkoeping University

Related
12 trials

Shared therapeutic areas:

DepressionAnxiety Disorders
Similarity Score6%

Hesheng Liu, Ph.D.

Changping Laboratory

Related
20 trials

Shared therapeutic areas:

Major Depressive DisorderDepressive Disorder, Treatment-Resistant
Similarity Score6%

Olivier Beauchet, MD

Jewish General Hospital

Related
19 trials

Shared therapeutic areas:

Depression
Similarity Score3%

Publications (0)

No publications found for this investigator.

Clinical Trials (8)

Showing 8 of 8 trials

NCT07623135Phase 3PrincipalInvestigator

Lumateperone for Late-Life Depression

Depression / Major Depressive DisorderLate Life Depression (LLD)Treatment Resistant Depression (TRD)
Recruiting
NCT04342663Phase 2PrincipalInvestigator

A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection

CoronavirusCOVID 19
Completed
NCT05124132Not ApplicablePrincipalInvestigator

Resilience and Brain Health of Older Adults (MEDEX-2)

Age-related Cognitive Decline
Enrolling By Invitation
NCT02181231Phase 1/2PrincipalInvestigator

Buprenorphine Used With Treatment Resistant Depression in Older Adults

DepressionMajor Depressive Disorder
Completed
NCT02665481Not ApplicablePrincipalInvestigator

Mindfulness-Based Stress Reduction, Health Education and Exercise

Age-related Cognitive Decline
Completed
NCT02099825Phase 1PrincipalInvestigator

Medication Enhanced Rapid Therapy

Anxiety Disorders
Terminated
NCT00951691Phase 2PrincipalInvestigator

Enhanced Medical Rehabilitation for Disablement

DepressionHip Fracture
Completed
NCT01333098Phase 1/2PrincipalInvestigator

Antiglucocorticoid Therapy for Cognitive Impairment in Late-life Anxiety Disorders

Anxiety Disorders
Completed

All 8 trials loaded